Milestone payment of $4.00 per CVR received 9/10/18.

Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema (8/23/18)

- In the pivotal study, patients taking TAKHZYRO 300 mg every 2 weeks had an 87% reduction in mean monthly attacks vs. placebo (0.26 vs. 1.97, n=27 vs. n=41)

- All secondary endpoints were met and included reduction in moderate or severe attacks and attacks requiring acute treatment

- According to an exploratory endpoint, there were patients receiving TAKHZYRO 300 mg every 2 weeks who had zero attacks during the study

- TAKHZYRO is a subcutaneous injection that took the majority of patients one minute or less to self-administer

Dublin, Ireland – August 23, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the leading global biotechnology company focused on rare diseases, today announced that following priority review, the U.S. Food and Drug Administration (FDA) has approved TAKHZYRO™ (lanadelumab-flyo) injection, for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older. HAE is a rare, genetic and potentially life-threatening disorder that can result in recurrent attacks of edema (swelling) in various parts of the body.1,2,3,4

“HAE attacks are painful, debilitating, and potentially life threatening. TAKHZYRO provides the HAE community with a new option for the prevention of HAE attacks,” said Anthony J. Castaldo, President, U.S. Hereditary Angioedema Association. “We are grateful for the time and effort put forth by the patients and researchers who participated in the clinical trial program that enabled this important addition to the HAE treatment landscape.”

TAKHZYRO is the only monoclonal antibody (mAb) that provides targeted inhibition of plasma kallikrein, an enzyme which is chronically uncontrolled in people with HAE, to help prevent attacks. The recommended starting dose of TAKHZYRO is 300 mg every two weeks. A dosing interval of 300 mg every four weeks is also effective and may be considered if the patient is well-controlled (e.g., attack free) for more than six months.

In the Phase III HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ supporting FDA approval, TAKHZYRO reduced the number of monthly HAE attacks an average of 87% (n=27) vs. placebo (n=41) when administered at 300 mg every two weeks and 73% (n=29) vs placebo (n=41) when administered at 300 mg every four weeks (Adjusted P<0.001).5

In the 26-week clinical study, which included 125 people with HAE, patients taking TAKHZYRO 300 mg every 2 weeks also had 83% fewer moderate to severe attacks, and 87% fewer attacks that needed on-demand treatment. A pre-specified, exploratory analysis showed that 44% of patients (n=27) receiving TAKHZYRO 300 mg every two weeks had zero attacks compared to placebo (2%, n=41) for the 26-week treatment period from Day 0 to Day 182. Additionally, in a post hoc analysis of the 16-week period from Day 70 to Day 182, 77% of patients (n=26) treated with TAKHZYRO in the same dosage arm of the trial were attack-free compared to placebo (3%, n=37).

TAKHZYRO has a half-life of approximately two weeks and is administered as one subcutaneous self-injection every two weeks at the recommended starting dose. In clinical trials, the majority of patients took one minute or less to complete the injection.5 The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea.

Andreas Busch, Ph.D., Executive Vice President, Head of Research and Development at Shire said: “With the approval of TAKHZYRO, HAE patients have an innovative treatment that works differently than current options to help prevent attacks. Based on an exploratory and post hoc analysis, after six doses of TAKHZYRO 300 mg every two weeks, 77% or nearly 8 of 10 patients had zero attacks. This approval reinforces our ongoing commitment to developing novel therapies that have a meaningful impact on patients. Looking to the future, we continue to work towards our goal of a world in which those living with HAE can aim for zero attacks.”

The FDA approval of TAKHZYRO was based on data from four clinical trials, including the HELP Study™, the largest prevention study conducted to date in HAE. Of the patients who completed the HELP Study™ who received TAKHZYRO, 97% opted in to an ongoing open-label extension study designed to evaluate the long-term safety and efficacy of TAKHZYRO.

Shire added TAKHZYRO to its HAE portfolio with the acquisition of Dyax Corp., which was completed in January 2016 in an all cash transaction valued at approximately $5.9 billion. Under the terms of the acquisition, the non-tradable contingent value right (CVR) received by Dyax shareholders will now pay $4.00 in cash per Dyax share as a result of the FDA approval of TAKHZYRO (formerly DX-2930).

About The HELP Study™
The HELP Study™ was a global, multicenter, randomized, double-blind placebo-controlled parallel group trial that evaluated the efficacy and safety of subcutaneously administered TAKHZYRO versus placebo over 26 weeks in 125 patients 12 years of age or older with HAE.6

The primary endpoint was the number of investigator-confirmed HAE attacks over the entire 26-week study duration. TAKHZYRO demonstrated that subcutaneous injections every two or four weeks reduced the mean monthly number of attacks across all three TAKHZYRO treatment arms studied: 300 mg every two weeks, 300 mg every four weeks, and 150 mg of TAKHZYRO every four weeks.6 At 300 mg every two weeks, TAKHZYRO reduced the number of mean monthly HAE attacks by 87% vs. placebo (Adjusted P<0.001).

Secondary endpoints included: 1) number of attacks requiring acute treatment and 2) number of attacks assessed as moderate or severe. Overall, each TAKHZYRO treatment arm demonstrated statistically significant attack rate reductions compared with placebo for all secondary efficacy endpoints (Adjusted P<0.001 for all comparisons), including: attacks requiring acute treatment (74% to 87%) and moderate or severe attacks (70% to 83%).

The most frequent adverse events occurring in ≥10% of patients taking TAKHZYRO were injection site reactions (52%), followed by upper respiratory infection (29%), and headache (21%). Hypersensitivity reactions have occurred in few patients (1%) and were non-serious. No anaphylaxis and no anaphylactoid reactions have been observed. In case of a severe hypersensitivity reaction, patients should discontinue TAKHZYRO and seek appropriate treatment.

The HELP Study™ Extension
The long-term safety and efficacy of TAKHZYRO for prophylaxis to prevent HAE attacks continues to be evaluated in an open-label extension study. The primary objective of the HELP extension study is to investigate the long-term safety of TAKHZYRO. At the time of interim analysis, the average length of time subjects have been exposed to TAKHZYRO is 8.2 months (SD=2.2). Interim safety data is consistent with controlled safety data from the HELP study.

In the extension study, 212 adolescent and adult patients received at least one dose of TAKHZYRO. Of these, 109 patients are rollover participants from the HELP Study™ and 103 are new or non-rollover participants who had a historical baseline attack rate of >1 attack per 12 weeks and a confirmed diagnosis of HAE. The median age of this study population is 43 years with a range of 12 to 76.

About TAKHZYRO™ (lanadelumab-flyo) injection
TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein and is indicated for prophylaxis to prevent HAE attacks in patients 12 years and older. TAKHZYRO is formulated for subcutaneous administration and has a half-life of approximately two weeks.7 TAKHZYRO is intended for self-administration or administration by a caregiver. The patient or caregiver should be trained by a healthcare professional.

U.S. Indication and Important Safety Information
INDICATION
TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION
Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp. (a wholly-owned, indirect subsidiary of Shire plc) at 1-800-828-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

Shire’s Commitment to Hereditary Angioedema
HAE is a rare, genetic disorder estimated to affect about 1 in 10,000 to 1 in 50,000 people worldwide.1,2 The condition results in recurring attacks of edema (swelling) in various parts of the body, including the abdomen, face, feet, genitals, hands, and throat that can be debilitating and painful. Laryngeal attacks that obstruct the airways are potentially life-threatening due to the risk of asphyxiation.1,3, 4

Shire is a dedicated, long-term partner to the HAE community with a decade of experience supporting patients. We are committed to serial innovation in HAE and our portfolio of products includes a number of therapy options to help meet the individual needs of those living with the disease. Beyond our focus on developing novel treatments, we provide specialized services and support offerings tailored to the HAE community. Learn more at shire.com.

For further information please contact:

Investor Relations

Christoph Brackmann
christoph.brackmann@shire.com
+41 41 288 41 29
Sun Kim
sun.kim@shire.com
+1 617 588 8175
Scott Burrows
scott.burrows@shire.com
+41 41 288 4195

Media

Katie Joyce
kjoyce@shire.com
+1 781 482 2779
Emily Bunting
emily.bunting@shire.com
+41 79 866 9703

For all questions related to Dyax CVR, contact American Stock Transfer & Trust Company, LLC:
Shareholder Services
+1 800 937 5449 or out of USA + 1 718 921 8300
help@astfinancial.com
www.astfinancial.com

NOTES TO EDITORS

Stephen Williams, Deputy Company Secretary, is responsible for arranging the release of this announcement.

Inside Information

This announcement contains inside information.

About Shire

Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, Ophthalmics, and Oncology.

Championing patients is our call to action - it brings the opportunity - and responsibility - to change people’s lives.

www.shire.com

https://globenewswire.com/news-release/2018/08/23/1556201/0/en/Shire-Announces-FDA-Approval-of-TAKHZYRO-lanadelumab-flyo-a-First-of-its-Kind-mAb-Preventive-Treatment-for-Hereditary-Angioedema.html

Milestone payment of $4.00 per CVR upon approval of DX-2930 by 12/31/19.

Please note that this CVR is non-tradeable.

Shareholder's Meeting scheduled for 1/21/16 at 1:00.

Investing With An Edge: Dyax Corp. (12/07/15)

http://seekingalpha.com/article/3734516-investing-with-an-edge-dyax-corp

Proxy Statement (12/14/15)

http://www.sec.gov/Archives/edgar/data/907562/000119312515402574/d63203ddefm14a.htm

TDA says Shire agrees to acquire DYAX for $37.30/share with FTC clearance and potential CVR of $4/share.

Dyax ($DYAX -0.83%) jumped over 10% in after-hours trading after it said its deal to acquire Shire Pharmaceuticals International cleared an anti-trust review by the U.S. Federal Trade Commission.

CONGRATS!!!

Entered a day early but went short as well.

Entered a short position at open. Waiting for the early buying pressure to subside.

I'm Short & ready for that to happen. Tic toc ...

Looks like this may fall like bricks over the next couple of days.

$DYAX recent news/filings

bullish
quick trade, still good long term

## source: finance.yahoo.com

Thu, 02 Apr 2015 22:09:43 GMT ~ Most active Nasdaq-traded stocks


read full: http://sg.finance.yahoo.com/news/most-active-nasdaq-traded-stocks-172145872--finance.html
*********************************************************

Thu, 02 Apr 2015 22:09:43 GMT ~ Nasdaq stocks posting largest percentage increases

[AP] - A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: Tonix Pharma rose 26.5 percent to $7.40. Trillium Therapeutic rose 16.4 percent to $11.12. Ebix Inc. rose 14.3 percent to ...

read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-percentage-220237991--finance.html
*********************************************************

Thu, 02 Apr 2015 22:09:43 GMT ~ Nasdaq stocks posting largest volume increases


read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-volume-220410239--finance.html
*********************************************************

Thu, 02 Apr 2015 11:31:17 GMT ~ How RBC Capital Called A 50% Gain In This Biotech Stock


read full: http://finance.yahoo.com/news/rbc-capital-called-50-gain-113117299.html
*********************************************************

Wed, 01 Apr 2015 22:40:10 GMT ~ Dyax's Hereditary Angioedema Drug Meets Primary Endpoint - Analyst Blog


read full: http://finance.yahoo.com/news/dyaxs-hereditary-angioedema-drug-meets-224010567.html
*********************************************************

$DYAX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$DYAX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/DYAX/company-info
Ticker: $DYAX
OTC Market Place: Not Available
CIK code: 0000907562
Company name: Dyax Corp.
Incorporated In: DE, USA

$DYAX share structure

## source: otcmarkets.com

Market Value: $3,700,165,145 a/o Apr 02, 2015
Shares Outstanding: 136,789,839 a/o Feb 23, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01

$DYAX extra dd links

Company name: Dyax Corp.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=DYAX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=DYAX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=DYAX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/news - http://finance.yahoo.com/q/h?s=DYAX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/DYAX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=DYAX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/DYAX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Dyax+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Dyax+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Dyax+Corp.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/DYAX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000907562&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=DYAX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=DYAX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=DYAX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=DYAX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=DYAX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=DYAX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=DYAX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/DYAX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=DYAX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/DYAX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=DYAX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/DYAX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/DYAX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/DYAX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=DYAX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=DYAX



$DYAX DD Notes ~ http://www.ddnotesmaker.com/DYAX

I have made a nice pile of cash on this pick.. Been in about 1.5 yrs and finally paying off!

$DYAX DD Notes ~ http://www.ddnotesmaker.com/DYAX

bullish
long term buy and hold

$DYAX recent news/filings

## source: finance.yahoo.com

Wed, 10 Dec 2014 11:17:29 GMT ~ Can Dyax (DYAX) Keep the Earnings Streak Alive This Quarter?


read full: http://finance.yahoo.com/news/dyax-dyax-keep-earnings-streak-111729524.html
*********************************************************

Wed, 03 Dec 2014 12:27:24 GMT ~ Dyax Corp. to Participate in the 25th Annual Oppenheimer Healthcare Conference

[at noodls] - BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the 25th Annual Oppenheimer Healthcare Conference being held December 10-11, ...

read full: http://www.noodls.com/view/66B345637E8911076E78882199B10AEFA85A1EF2
*********************************************************

Wed, 03 Dec 2014 12:00:00 GMT ~ Dyax Corp. to Participate in the 25th Annual Oppenheimer Healthcare Conference

[Business Wire] - Dyax Corp. announced today that executive management will participate in the 25th Annual Oppenheimer Healthcare Conference being held December 10-11, 2014 at the Crowne Plaza Hotel in New York City.

read full: http://finance.yahoo.com/news/dyax-corp-participate-25th-annual-120000064.html
*********************************************************

Mon, 24 Nov 2014 15:00:00 GMT ~ Strong On High Relative Volume: Dyax (DYAX)


read full: http://www.thestreet.com/story/12964867/1/strong-on-high-relative-volume-dyax-dyax.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Tue, 18 Nov 2014 14:59:25 GMT ~ Dyax Corp. Recognized as a "Top Place to Work" by The Boston Globe

[at noodls] - BURLINGTON, Mass--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, today announced ...

read full: http://www.noodls.com/view/A97583FE6642B099A33AFF740256CAE653B2D54A
*********************************************************


$DYAX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$DYAX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/DYAX/company-info
Ticker: $DYAX
OTC Market Place: Not Available
CIK code: 0000907562
Company name: Dyax Corp.
Incorporated In: DE, USA


$DYAX share structure

## source: otcmarkets.com

Market Value: $1,980,722,307 a/o Dec 17, 2014
Shares Outstanding: 136,413,382 a/o Oct 28, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$DYAX extra dd links

Company name: Dyax Corp.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=DYAX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=DYAX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=DYAX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/news - http://finance.yahoo.com/q/h?s=DYAX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/DYAX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=DYAX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/DYAX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Dyax+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Dyax+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Dyax+Corp.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/DYAX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000907562&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=DYAX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=DYAX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=DYAX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=DYAX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=DYAX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=DYAX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=DYAX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/DYAX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=DYAX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/DYAX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=DYAX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/DYAX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/DYAX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/DYAX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=DYAX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=DYAX



$DYAX DD Notes ~ http://www.ddnotesmaker.com/DYAX

$DYAX recent news/filings

bullish

## source: finance.yahoo.com

Wed, 23 Jul 2014 12:02:00 GMT ~ 8:02 am Dyax announces publication of scientific data for DX-2930 in peer-reviewed journals; first paper describes the positive results from first-in-human clinical study of DX-2930 which met all of its objectives of assessing safety, toler


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#dyax
*********************************************************

Wed, 23 Jul 2014 12:00:00 GMT ~ Dyax Corp. Announces Publication of Scientific Data for DX-2930 in Peer-Reviewed Journals

[Business Wire] - Dyax Corp. today announced the online publication of scientific data for DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein , in two peer-reviewed journals.

read full: http://finance.yahoo.com/news/dyax-corp-announces-publication-scientific-120000050.html
*********************************************************

Tue, 15 Jul 2014 13:49:32 GMT ~ Dyax Corp. to Host Second Quarter 2014 Earnings Call and Webcast

[at noodls] - BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) will host a webcast and conference call, including an open question and answer session, Tuesday, July 29, 2014. During the call, management ...

read full: http://www.noodls.com/view/3006B616FC3861F800CC51846D172ADAA14D09DE
*********************************************************

Tue, 15 Jul 2014 12:59:00 GMT ~ Dyax Corp. to Host Second Quarter 2014 Earnings Call and Webcast

[Business Wire] - Dyax Corp. will host a webcast and conference call, including an open question and answer session, Tuesday, July 29, 2014. During the call, management will discuss t

read full: http://finance.yahoo.com/news/dyax-corp-host-second-quarter-125900445.html
*********************************************************

Mon, 30 Jun 2014 14:09:00 GMT ~ Today's Perilous Reversal Stock: Dyax (DYAX)


read full: http://www.thestreet.com/story/12760691/1/todays-perilous-reversal-stock-dyax-dyax.html?puc=yahoo&cm_ven=YAHOO
*********************************************************


$DYAX charts

basic chart ## source: stockcharts.com



basic chart ## source: eoddata.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$DYAX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/DYAX/company-info
Ticker: $DYAX
OTC Market Place: Not Available
CIK code: 0000907562
Company name: Dyax Corp.
Incorporated In: DE, USA


$DYAX share structure

## source: otcmarkets.com

Market Value: $1,195,052,505 a/o Jul 22, 2014
Shares Outstanding: 135,801,421 a/o Apr 25, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$DYAX extra dd links

Company name: Dyax Corp.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=DYAX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=DYAX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=DYAX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/news - http://finance.yahoo.com/q/h?s=DYAX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/DYAX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=DYAX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/DYAX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Dyax+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Dyax+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Dyax+Corp.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/DYAX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000907562&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=DYAX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=DYAX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=DYAX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=DYAX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=DYAX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=DYAX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=DYAX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/DYAX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=DYAX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/DYAX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=DYAX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/DYAX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/DYAX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/DYAX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/DYAX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/DYAX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=DYAX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=DYAX



$DYAX DD Notes ~ http://www.ddnotesmaker.com/DYAX
jkflb

DYAX NEW$= http://ih.advfn.com/p.php?pid=nmona&article=62358745&symbol=DYAX

8:01AM Dyax Receives Orphan Drug Designation from the FDA for DX-2930 in Hereditary Angioedema (DYAX) 8.40 : Co announced that the FDA has granted orphan drug designation to its drug candidate DX-2930, its fully human monoclonal antibody inhibitor of plasma kallikrein, for use in the treatment of hereditary angioedema (HAE). Dyax is developing DX-2930 to be a long-acting, prophylactic agent that prevents HAE attacks. Development plans include a dosage formulation that will permit infrequent self-administration by small volume, subcutaneous injection. DX-2930 is currently being studied in a placebo-controlled, dose-escalation Phase 1 trial in normal individuals. Results from this study are expected in the first quarter of 2014.

Dyax Receives Orphan Drug Designation from the U.S. FDA for DX-2930 in Hereditary Angioedema

BURLINGTON, Mass.--(BUSINESS WIRE)--December 05, 2013--
Dyax Corp. (NASDAQ:DYAX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its drug candidate DX-2930, its fully human monoclonal antibody inhibitor of plasma kallikrein, for use in the treatment of hereditary angioedema (HAE).

Dyax is developing DX-2930 to be a long-acting, prophylactic agent that prevents HAE attacks. Development plans include a dosage formulation that will permit infrequent self-administration by small volume, subcutaneous injection. DX-2930 is currently being studied in a placebo-controlled, dose-escalation Phase 1 trial in normal individuals. Results from this study are expected in the first quarter of 2014.

"Through our experience in the development and commercialization of KALBITOR(R) (ecallantide), we have gained a deep understanding of the HAE market and patient needs," said Gustav Christensen, President and Chief Executive Officer of Dyax. "There is still a significant unmet medical need within the HAE community which we plan to address with DX-2930. Orphan drug designation is an important element of our development strategy for DX-2930 as we work to further improve the health and quality of life for individuals suffering from this painful and often debilitating condition."

Orphan drug designation is granted by the FDA Office of Orphan Drug Products to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides FDA assistance in clinical trial design, an exemption from FDA user fees and eligibility for a seven-year period of market exclusivity in the U.S. after product approval.

About DX-2930

Discovered using Dyax's proprietary phage display technology platform, DX-2930 is a novel, fully human monoclonal antibody inhibitor of plasma kallikrein. Uncontrolled plasma kallikrein activity leads to excessive generation of bradykinin, a vasodilator thought to be responsible for the localized swelling, inflammation and pain characteristically associated with HAE. Preclinical studies suggest that DX-2930 will have a long half-life in humans, offering the potential for a long-acting and sustained therapeutic effect with less frequent dosing. Dyax is currently developing DX-2930 as a subcutaneous injection for the prevention of HAE attacks and the candidate is currently in a Phase 1 clinical trial.

About Hereditary Angioedema (HAE)

HAE is a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia, and larynx. HAE is caused by low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits plasma kallikrein, a key mediator of inflammation, and other serine proteases in the blood. HAE is estimated to affect up to 1 in 50,000 individuals. Learn more at www.HAEHope.com.

About Dyax

Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company's key value drivers are the KALBITOR(R) business, DX-2930 and Dyax's Licensing and Funded Research Program (LFRP).

For additional information about Dyax, please visit www.dyax.com.

http://online.wsj.com/article/PR-CO-20131205-905897.html?dsk=y

DYAX @ Stockcharts

Nice trend movement..giddy up!

http://finance.yahoo.com/news/dyax-corp-participate-2013-deutsche-130000921.html

http://finance.yahoo.com/news/dyax-corp-announces-five-hae-133000194.html

gonna be a tasty short soon I'm drooling!

Form 8-K for DYAX CORP 29-Aug-2013

Termination of a Material Definitive Agreement

Item 1.02. Termination of a Material Definitive Agreement.
On August 23, 2013, Dyax Corp. ("Dyax") and US Bioservices Corporation ("US Bio") entered into the First Amendment (the "Amendment") to the Hub Services Agreement between Dyax and US Bio entered into in February 2013. Pursuant to the Amendment, US Bio will stop providing Dyax with telephonic hotline support, referral intake, patient enrollment, access and reimbursement support, call triage, referral triage and general patient support services (the "Hub Services") effective September 30, 2013 (the "Termination Date"). The Amendment provides for transition services by US Bio through the Termination Date.

Dyax is in discussions with an alternative vendor of Hub Services and expects to enter into a new agreement to provide these services on or before the Termination Date.

Certain information included in this current report is forward-looking in nature within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including our expectation that we will enter into a new Hub Services agreement on or before the Termination Date. The forward-looking statements in this report are based on our current good faith beliefs; however, actual results may differ due to inaccurate assumptions regarding our ability to negotiate such an agreement in a timely manner.

Dyax Corp. Announces Dosing of First Subject in Phase 1 Trial of DX-2930 for Prevention of HAE Attacks
Business WirePress Release: Dyax Corp. – 1 hour 57 minutes ago

BURLINGTON, Mass.--(BUSINESS WIRE)--
Dyax Corp. (DYAX) today announced dosing of the first subject in a Phase 1 clinical study evaluating the safety and tolerability of single subcutaneous administration of DX-2930, its fully human monoclonal antibody inhibitor of plasma kallikrein. Dyax, a biopharmaceutical company focused on hereditary angioedema (HAE) and other plasma kallikrein-mediated disorders, is developing DX-2930 as a subcutaneous injection for prevention of HAE attacks. DX-2930 was discovered using Dyax’s proprietary phage display technology platform.
“There is significant need for a highly effective, safe and well tolerated prophylactic agent to treat HAE,” said Burt Adelman M.D., Executive Vice President and Chief Medical Officer at Dyax. “DX-2930 is a highly potent, long-acting, fully human monoclonal antibody that binds specifically to active plasma kallikrein. We look forward to completing this study and moving forward rapidly with this important clinical program.”
This Phase 1, single-center, randomized, double-blind, placebo-controlled study is designed to assess the safety and tolerability and to characterize the pharmacokinetics (PK) of single, subcutaneous administrations of DX-2930 in healthy subjects. Approximately 32 subjects will be enrolled into four ascending dose cohorts (n=8 per cohort) of DX-2930 or placebo. The study will be conducted at the clinical trials unit of Vince & Associates Clinical Research, a recognized “Center of Research Excellence”, located in Overland Park, Kansas.
“The successful dosing of the first subject in this Phase 1 clinical study is an important milestone for the DX-2930 development program,” said Gustav Christensen, President and CEO of Dyax. “We believe our knowledge of the plasma kallikrein pathway provides us with unique insight and a significant advantage in developing and commercializing this product candidate.”
About DX-2930
Discovered using Dyax’s proprietary phage display technology platform, DX-2930 is a novel, fully human monoclonal antibody inhibitor of plasma kallikrein. Uncontrolled plasma kallikrein activity leads to excessive generation of bradykinin, a vasodilator thought to be responsible for the localized swelling, inflammation and pain characteristically associated with HAE. Preclinical studies suggest that DX-2930 will have a long half-life in humans, offering the potential for a long-acting and sustained therapeutic effect with less frequent dosing. Dyax is currently developing DX-2930 as a subcutaneous injection for the prevention of HAE attacks.
About HAE
HAE is a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia, and larynx. HAE is caused by low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits plasma kallikrein, a key mediator of inflammation, and other serine proteases in the blood. HAE is estimated to affect up to 1 in 50,000 individuals. Learn more at www.HAEHope.com.
About Dyax
Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company's key value drivers are the KALBITOR® (ecallantide) business, DX-2930 and the Licensing and Funded Research Program (LFRP).
Dyax developed KALBITOR on its own and, since February 2010, has been selling it in the United States for the treatment of acute attacks of HAE in patients 16 years of age and older. Outside the United States, the Company has established partnerships to obtain regulatory approval and commercialize KALBITOR in certain markets and is evaluating opportunities in others.
The Company is developing products to expand its angioedema portfolio, including a therapeutic candidate, DX-2930, for the prophylactic treatment of HAE and a diagnostic test to identify plasma kallikrein-mediated disorders.
KALBITOR and DX-2930 were identified using Dyax's patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 13 revenue generating product candidates in various stages of clinical development, including three in Phase 3 trials.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com.

Thx much!!

I stopped watching it but one glance at the chart and I can tell you it's running into resistance soon. Whether or not it can make it through will depend on how much buying pressure there is. 3.25 is the next area of resistance to keep an eye on. Good luck.

Any estimates on how high this go

7:17AM Dyax prices registered direct offering with RA Capital Management, Venrock, Federated Investors and one other institutional investor for gross proceeds of ~ $30 mln; offering was priced at $2.30 per share (DYAX) 2.31 : A total of 8,901,675 million shares of common stock and 41,418 shares of Series 1 convertible preferred stock are expected to be issued at closing. Each share of Series 1 convertible preferred stock was priced at $230 and is convertible into 100 shares of common stock.

DYAX seems like is going to pop very soon. GLTA!

7:49AM On The Wires (WIRES) :Dyax (DYAX) and CVie Therapeutics, a subsidiary of Lee's Pharmaceutical Holdings, announced a strategic partnership for the development and commercialization of KALBITOR (ecallantide) in the treatment of hereditary angioedema and other angioedema indications in China, Hong Kong and Macau.

Any specific reasons for saying that?

$DYAX more upside come on!

SIA-Chart on DYAX : Very Bullish : Besides having a superman show up, which happens when the stock goes 5% above its 100 day moving average. We also have a super cross show up which means that the 50 day moving average has broken above the 100 day moving average, which is also very bullish and means that buyers are coming in big time.

SURF IM NOW WATCHING DYAX WHY DO YOU LIKE DYAX AND WHERE DO U SEE IT GOING AND WHY

7:30AM Dyax and Kadmon sign strategic licensing agreement for DX-2400 (DYAX) 2.52 : The cos have entered into a strategic licensing agreement in which Kadmon has been granted an exclusive worldwide license for the development and commercialization of the fully human monoclonal antibody DX-2400, a potent and selective antibody inhibitor of matrix metalloproteinase 14 (MMP-14). MMP-14 is a key enzyme in a molecular pathway thought to play a role in tumor blood vessel formation (angiogenesis) in addition to affecting tumor growth and cell migration. Under the terms of the agreement, Dyax will receive an upfront payment, and is eligible for significant development and commercial milestone payments, in addition to tiered royalties on commercial sales up to a double-digit rate. As an exclusive licensee, Kadmon will be responsible for further development and commercialization of DX-2400, which is currently in investigational new drug (IND) application-enabling studies.

7:13AM Dyax announces the appointment of Ivana Magovcevic-Liebisch to the new position of Executive Vice President, Chief Operating Officer (DYAX) 2.46 : Dr. Magovcevic-Liebisch joined Dyax in April 2001, and has served as an executive officer at the Company since 2005.

DYAX halted the trial. $1.95. Dyax calls early halt to Kalbitor clinical trial
Dyax stops mid-stage trial of Kalbitor because drug was not working better than placebo
Associated PressAssociated Press – 15 hours ago


RELATED QUOTES
Symbol Price Change
DYAX 1.92 -0.22

BURLINGTON, Mass. (AP) -- Dyax Corp. said Thursday it is stopping a clinical trial of its angioedema drug Kalbitor because the drug was not working better than a placebo.

Kalbitor is approved as a treatment for acute attacks of hereditary angioedema, a rare genetic disorder that can cause dangerous swelling of the throat or larynx. Dyax is also studying the drug as a treatment for angioedema attacks caused by a group of drugs called ACE inhibitors. The drugs are used to treat high blood pressure and other conditions and angioedema is a known side effect.

The company said it is assessing its options in developing treatments for angioedema that is caused by ACE inhibitors.

Dyax said initial data from the mid-stage trial showed that Kalbitor was not significantly more effective than a placebo. In part that was because patients who were given the placebo did better than expected. The trial was designed to show that patients who took Kalbitor would be more likely to meet criteria that would allow them to be discharged from emergency rooms six hours after being treated.

Dyax said safety concerns did not play any part in its decision to end the study.

Shares of Dyax rose 7 cents, or 3.4 percent, to close Thursday at $2.14. The stock sank 24 cents, or 11.2 percent, to $1.90 after hours following the announcement.

8:04AM Dyax extends partnership with Bayer (BAYRY) for access to co's Fully-Human Antibody Phage Display Library (DYAX) 1.79 :

DYAX Chart & Analysis – Nice setup on this Nasdaq stock above $1 + plenty of liquidity

http://onlycharts.com/2012/05/24/dyax-chart-analysis-nice-setup-on-this-nasdaq-stock-above-1-plenty-of-liquidity/

7:27AM On The Wires (WIRES) : Dyax Corp. (DYAX) and Eclipse Therapeutics announced that Dyax has granted Eclipse an exclusive worldwide license for the development and commercialization of preclinical fully-human antibodies discovered using Dyax's gold-standard phage display technology for use in oncology indications.

2:17AM Dyax and GE Healthcare announce licensing agreement for c-Met imaging peptides for use in colorectal, lung and liver cancer research (DYAX) 1.56 :

7:44AM Dyax announced presentation of data from Kalbitor clinical studies: low rebound and relapse rates observed (DYAX) 1.46 : Henry Li, M.D., Ph.D. of the Institute for Asthma and Allergy in Wheaton, MD said, "Taken together, the results presented today enrich the KALBITOR efficacy profile and provide further support for its use against acute attacks of hereditary angioedema. Notably, low rebound and relapse rates observed among patients treated with KALBITOR evidence sustained relief from HAE attacks, an important consideration in selecting therapy

7:19AM Dyax appoints Dr. Burt Adelman as Chief Medical Officer (DYAX) 1.48 : Dr. Adelman will lead the development and regulatory strategy for the co's non-histamine-mediated angioedema franchise.

~ Monday! $DYAX ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $DYAX ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=DYAX&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=DYAX&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=DYAX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=DYAX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=DYAX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=DYAX
Finviz: http://finviz.com/quote.ashx?t=DYAX
~ BusyStock: http://busystock.com/i.php?s=DYAX&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=DYAX >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

Form 8-K for DYAX CORP
4-Jan-2012
Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation o

Item 1.01. Entry into a Material Definitive Agreement.

On December 29, 2011, Dyax Corp. ("Dyax" or the "Company") entered into a Loan Agreement with LFRP Investors, L.P., an affiliate of Cowen Healthcare Royalty Management, LLC ("Lender"). The Loan Agreement provides for an unsecured loan by Lender of $20,000,000 (the "Tranche A Loan"), which was funded on the date of the Loan Agreement. The Loan Agreement also provides for a subsequent loan (the "Tranche B Loan") that will be used to refinance amounts outstanding under the Amended and Restated Loan Agreement dated as of March 18, 2009 by and between the Company and Vanderbilt Royalty Sub L.P. (the "Existing Loan") and will be secured by the Company's Licensing and Funded Research Program (the "LFRP") in substantially the same manner as the Existing Loan. Subject to customary closing conditions, on or about August 22, 2012 (the "Tranche B Closing Date"), Lender will lend to the Company and the Company will borrow an amount equal to the lesser of (i) 100% of the amount necessary to repay in full any and all amounts outstanding under the Existing Loan and (ii) $60,000,000 and will issue a note to Lender with an original principal amount stated as 102% of the principal amount of the loan.

Until the Tranche B Loan is funded, the Tranche A Loan will bear interest at a rate equal to 13% per annum and all accrued interest thereon will be capitalized and added to principal. The Tranche A Loan will mature on June 30, 2013; provided, however, that, from and after funding of the Tranche B Loan, the maturity date of the Tranche A Loan shall be August 22, 2018 (the "Maturity Date"). Upon funding of the Tranche B Loan, interest payable on the Tranche A Loan will decrease to 12% per annum and will amortize on the same terms as the Tranche B loan, as described below. In addition, upon the funding of the Tranche B Loan or, if earlier, repayment of all amounts outstanding under the Existing Loan, the Tranche A Loan will be secured, on an equal and ratable basis with the Tranche B Loan.

The Tranche B Loan and the Tranche A Loan (upon funding of the Tranche B Loan, collectively, the "Loans") will amortize quarterly on January 15, April 15, July 15 and October 15, (each an "Interest Payment Date") of each year, beginning on the first Interest Payment Date occurring after the funding of the Tranche B Loan and will bear interest at a rate of 12% per annum payable quarterly. On each Interest Payment Date, Dyax will repay the portion of the principal amount of the Loans equal to the Applicable Included Receipts (as defined below) for the prior fiscal quarter less any portion of the Applicable Included Receipts used to pay cash interest on both the Tranche A Loan and the Tranche B Loan. The balance of the outstanding principal amount of both the Loans, together with any accrued and unpaid interest, will be due on the Maturity Date.

The "Applicable Included Receipts" will be determined as follows: (i) prior to September 30, 2016, the sum of (a) 75.0% of the first $15.0 million in annual net royalties, milestones and license fees received by Dyax under the LFRP (the "Included Receipts") and (b) 25.0% of annual Included Receipts greater than $15 million, and (ii) after September 30, 2016, 90.0% of annual Included Receipts until the later of the Maturity Date and the complete repayment of the Loans. If the Applicable Included Receipts for any quarterly period are insufficient to cover the cash interest on the Loans due for that period (such deficiency, the "Deficiency Amount"), then the Deficiency Amount shall be paid in kind and deemed additional principal outstanding under the Loans. At its sole option, Dyax may pay the Deficiency Amount out of other funds.

Unless Lender fails to fund the Tranche B Loan on the Tranche B Closing Date as a result of Dyax's failure to meet certain closing conditions, Dyax may not prepay the Tranche A Loan prior to the funding of the Tranche B Loan.

Following funding of the Tranche B Loan, Dyax may prepay the Loans (x) in whole at any time or (y) in part from time to time after August 21, 2015 (the "No-Call Date") in any case at a prepayment price equal to 100% of the outstanding principal amount thereof prepaid, together with all accrued and unpaid interest on the principal amount prepaid; provided, however, that (i) the outstanding principal balance of the Loans after giving effect to any such voluntary partial prepayment shall not be less than $30,000,000 and (ii) each voluntary partial prepayment shall be in an amount that is an integral multiple of $30,000,000 and not less than $30,000,000 or, if less, the outstanding principal amount of the Loans; provided, further, that, if any voluntary prepayment (in whole) occurs prior to the No-Call Date, such prepayment shall be accompanied by the Prepayment Premium (defined below) with respect to the entire outstanding principal amount of the Loans.

In the event of a change of control, a merger or a sale of all or substantially all of Dyax's assets, any or all of Loans (at the option of Lender) shall be due and payable; provided that if such a transaction occurs prior to August 21, 2015, then such prepayment shall be accompanied by a prepayment premium equal to the aggregate amount of all required interest payments due on the Loan (or the applicable portion) through the No-Call Date less all interest paid in cash through the date of prepayment (the "Prepayment Premium").

Pursuant to the terms of the Loan Agreement, Dyax will enter into a security agreement on the Tranche B Closing Date granting Lender a security interest in substantially all of the assets related to the LFRP (the "Collateral"). The Collateral does not include rights to Dyax's current or future internal drug development or co-development programs.

The Loan Agreement provides that each of the following is an event of default ("Event of Default"): (a) default in payment of any principal or interest under the Loans; (b) any representation or warranty of Dyax in the Loan Agreement proves not to be true and correct when made and the failure of such statement, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect (as defined in the Loan Agreement); (c) default by Dyax in the observance or performance of any other covenant in the Loan Agreement that continues for 30 days after written notice from Lender and the failure could reasonably be expected to result in a Material Adverse Effect; (d) default by Dyax to perform or observe its covenants or agreements with respect to maintenance of its existence, preservation of the intellectual property related to the LFRP; (e) default by Dyax under outstanding Indebtedness (as defined in the Loan Agreement) in excess of $2,000,000 that results in the acceleration of the maturity of such Indebtedness; (f) sale or other disposition of the LFRP Intellectual Property (as defined in the Loan Agreement) or any Included Receipts by Dyax; (g) commencement of dissolution or bankruptcy proceedings by Dyax; (h) in connection with certain failures to perform the LFRP; and (i) if, following the repayment of the Existing Loan, the security interest in the Collateral ceases to be in full force and effect. If an Event of Default occurs, Lender can declare the Loans, all interest thereon and all other amounts payable under the Loan Agreement immediately due and payable.



Item 2.03. Creation of a Direct Financial Obligation or an Obligation Under
an Off-Balance Sheet Arrangement.

The information set forth under Item 1.01 of this current report on Form 8-K regarding the Loan Agreement is hereby incorporated by reference.

Important Cautionary Statement About Forward-Looking Statements:

The information in this report contains forward-looking statements, including statements regarding the funding of the Tranche B Loan. Statements that do not describe historical or current facts, including statements about beliefs and expectations, are forward-looking statements. These statements often include the words "believes," "expects," "anticipates," or similar expressions or future conditional verbs such as "will" "should," and "shall." Such statements are based upon the current beliefs and expectations of management and on information currently available to management. The forward-looking statements are intended to be subject to the safe harbor provided by Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements speak as of the date hereof, and the Company does not assume any obligation to update the statements made herein or to update the reasons why actual results could differ from those contained in such statements in light of new information or future events. Forward-looking statements are subject to significant risks and uncertainties. Investors are cautioned against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ materially from those described in the forward-looking statements include any failure by the Company to satisfy the closing conditions required for the Lender to be obligated to fund the Tranche B Loan and any changes in law that could affect the granting of the security in the Collateral required under the Loan Agreement, as well as those factors that can be found in the Company's filings with the Securities and Exchange Commission, including Item 1A ("Risk Factors") of its Annual Report on Form 10-K for the year ended December 31, 2010, as supplemented by the Risk Factors contained in its Quarterly Reports on Form 10-Q, and are incorporated by reference herein.

http://quotes.barrons.com/dyax/ownership

6. Dyax Corp. (DYAX): Biotechnology Industry. Market cap of $126.40M. Net institutional shares sold over the current quarter at 3.5M, which is 3.83% of the company's 91.43M share float. The stock is a short squeeze candidate, with a short float at 6.07% (equivalent to 8.26 days of average volume). The stock has performed poorly over the last month, losing 25.58%.

http://seekingalpha.com/article/290509-10-biotech-stocks-being-dumped-by-big-money-managers?source=yahoo

DYAX $1.28 up a bit on its competitor's aproval.

FDA Approves Shire's Treatment For Swelling Disorder
11:14a ET August 25, 2011 (Dow Jones)
FDA Approves Shire's Treatment For Swelling Disorder
DOW JONES NEWSWIRES

Shire PLC's (SHPGY, SHP.LN) treatment for a rare swelling disorder was approved by the U.S. Food and Drug Administration.
The drug, Firazyr, is the third drug approved in the U.S. to treat attacks of a rare condition called hereditary angioedema, according to the FDA.
Firazyr is the first on-demand treatment for hereditary agiodema that patients can inject themselves when they feel an attack coming on, instead of seeking a health-care professional. This rare disorder is a potentially fatal condition that causes severe swelling in the hands and feet, gastrointestinal tract and upper airway.
The other FDA approved treatments are CSL Behring's Berinert to treat facial and abdominal attacks of the condition, and Dyax Corp.'s (DYAX) Kalbitor to treat acute attacks in patients ages 16 years and older.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

7:16AM On The Wires (WIRES) :

Dyax Corp. (DYAX) announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme inhibitor-induced angioedema.

Dyax Corp. and Kadmon Corporation Announce Antibody Library License Agreement

Press Release Source: Dyax Corp. On Tuesday July 26, 2011, 7:00 am

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ:DYAX - News) and Kadmon Corporation, LLC (Kadmon) announced today that Dyax has granted Kadmon a non-exclusive license to Dyax’s proprietary “gold-standard” antibody phage display libraries for the discovery and development of therapeutic antibodies. Dyax’s human antibody phage libraries combine gene fragments from human donors with strategically designed synthetic DNA, and are used to identify high-affinity human antibodies that bind to numerous therapeutic targets, including cell surface proteins such as tumor cell markers, viral antigens, enzymes and glycoproteins.

Samuel D. Waksal, Ph.D., Chairman and CEO of Kadmon, said, “This agreement provides us with the opportunity to work with Dyax and their powerful, industry-leading technology to develop novel medicines targeting the pathways of proliferation and survival in disease. The team at Kadmon has extensive experience in collaborating with Dyax, having employed their technology to develop ImClone Systems’ significant oncology pipeline. We look forward to resuming our relationship with Dyax and to adding to our pipeline of medicines in oncology, infectious diseases, immunology and neurodegenerative diseases.”

“We are pleased to have entered into this agreement with Kadmon, a company whose scientific leadership clearly understands the versatility and strength of Dyax’s technology,” commented Gustav Christensen, President and Chief Executive Officer of Dyax. “Dyax continues to build value through the Licensing and Funded Research Program which, through its unmatched royalty portfolio, is expected to generate up to $85 million in revenue within the next five years. As our agreements extend ten years beyond first commercial sale, irrespective of patent expiry, this unique franchise will contribute to Dyax’s bottom line for many years to come.”

The terms of this strategic agreement include upfront and annual license fees, clinical and regulatory milestone payments. Dyax is also entitled to royalties on net sales of any products identified using Dyax’s technology that may be developed and commercialized by Kadmon. The agreement also provides Kadmon with sublicenses to relevant third-party antibody phage display patents related to Dyax’s technology.

About Dyax’s Phage Display

Dyax’s proprietary drug discovery technology, phage display, provides an efficient means to identify compounds that interact with a wide array of therapeutic targets. Dyax’s discovery capabilities have been further enhanced through automation, which has enabled the Company to evaluate a large number of molecules binding to each target. In this way, Dyax is able to rapidly identify and select a specific antibody, peptide or small protein with the desired biochemical and biological characteristics. Dyax’s state-of-the-art antibody phage display libraries allow for the rapid isolation of fully human target-specific antibodies from a library of billions of unique antibodies. These extensive libraries are screened using in vitro selection strategies that are tailored to increase the yield of lead candidates with the desired therapeutic properties.1,2